Genitourinary Cancer

Patients with neuroendocrine tumors are at greater risk for cancer-associated death compared with death due to other causes; however, mortality rates vary according to tumor site.

Standard eligibility criteria for pancreatic cancer clinical trials differentially exclude Black patients from participation, according to results a simulated screening process.

The FDA placed a clinical hold on a series of clinical trials that use Allogene Therapeutics’ AlloCAR T chimeric antigen receptor T-cell therapies, according to a press release from the manufacturer.

Removing race from estimated glomerular filtration rate equations could result in more Black patients being excluded from anticancer therapy, thus negatively affecting outcomes, according to study results published in The Lancet Oncology.

Patients with solid tumor cancers sustained similar COVID-19 antibody levels as individuals without cancer 6 months after the second dose of the mRNA COVID-19 vaccine, according to study results published in Cancer Discovery.

The addition of berzosertib to cisplatin and gemcitabine did not extend PFS among patients with metastatic urothelial cancer, according to results of a randomized phase 2 trial.

The Prostate Cancer Foundation named Charles J. Ryan, MD, as its president and CEO.

The FDA granted fast track designation to CT-0508 for treatment of patients with solid tumors that overexpress human epidermal growth factor receptor 2.

First-line nivolumab plus ipilimumab conferred durable survival benefit compared with sunitinib for patients with advanced renal cell carcinoma, according to results of the randomized phase 3 CheckMate-214 trial.

The FDA granted full approval to pembrolizumab for first-line treatment of certain patients with advanced urothelial carcinoma, according to the agent’s manufacturer.